<DOC>
	<DOCNO>NCT01904201</DOCNO>
	<brief_summary>The health immune system HIV infected people currently determine blood test measure number cluster differentiation 4 ( CD4 ) T lymphocytes . These cell play critical role immune response . Studies show low number ( normal range ) CD4 T lymphocytes indicates defect immune system . Conversely , number CD4 T lymphocytes within normal range generally indicate normal immune system . When person infect HIV CD4 T lymphocytes attack destroyed number decline mean immune system longer effectively protect body infection cancer . However , HIV infect person successfully treat Highly Active Antiretroviral Therapy ( HAART ) CD4 T lymphocytes number increase may end normal range immune system may still function properly number cell incapable function properly . It would interest know functional immune system rather number cell . For , QuantiFERON® Monitor ( QFM CST007 ) test experimental diagnostic test use study measure immune function people infect HIV . The objective study evaluate usefulness QFM test HIV infect people compare uninfected people measure function immune system . The QFM test measure interferon-gamma release plasma follow incubation heparinised whole blood combination stimulant . As immune function directly influence cell actively replicate HIV additional research test call HIV Reservoir Test include well understand level immune function study subject . How long take ? One visit 1 hour Dr. Gatpolintan Clinical Study Coordinator answer question , 10 minute blood draw ( nine block Dr. Gatpolintan ' office ) . Study outcome measure ( Correlation QFM CD4 count CD4/CD8 ratio ) assess , include data presentation , within average period 1 year study subject enrollment .</brief_summary>
	<brief_title>Evaluation Blood Test Measure Immune Function HIV Positive People Compared With HIV Negative People</brief_title>
	<detailed_description>Routine virologic immunologic test monitor HIV-1 infected individual highly active antiretroviral therapy ( HAART ) include CD4 T-cell enumeration , HIV-1 plasma viral load , HIV-1 genotypic resistance test baseline treatment-naive patient follow virologic failure HAART . The CD4 T-cell count measurement number T helper lymphocytes , conjunction CD4/cluster differentiation 8 ( CD8 ) ratio , surrogate marker evaluate status immune system use monitor progression define stag HIV disease infect subject either treatment . An increase high CD4 count CD4/CD8 ratio 1 4 suggests control virus replication result HAART ( inherent immune activity untreated subject ) decrease low CD4 count CD4/CD8 ratio &lt; 1 suggests HAART failure and/or deteriorate immune system . HIV-1 plasma viral load measure number HIV-1 RNA copy derive virus particle plasma . A detectable plasma viral load indicate HIV-1 replication undetectable plasma viral load suggest control HIV-1 replication . Nevertheless , low limit detection 50 copy HIV-1 RNA/mL commercial assay , low level plasma virus remain undetected assay detectable approximately 70 % patient HAART use research assay cutoff &lt; 50 copy HIV-1 RNA/ml . Such research base plasma viral load assay never use routine monitoring clinical care infected subject . While CD4 count HIV-1 plasma viral load inextricably related context HIV-1 disease currently approve test determine HIV-1 response HAART assay significant shortcoming effective treatment HIV define : - CD4 count immune dysfunction . Increasing high CD4 count normal CD4/CD8 ratio result HAART may necessarily represent uncompromised immune system represent state immune dysfunction result immune activation continue HIV replication . - HIV Cellular reservoir : Low level cell associate HIV replication undetected plasma standard plasma viral load assay . Cell associate HIV replication determine HIV polymerase chain reaction ( PCR ) extract purified total cell associate RNA in-situ hybridization cell associate HIV-1 RNA intact cell , detect approximately 62 % 80 % patient HAART plasma viral load &lt; 50 copy HIV-1 RNA/mL . Targeted treatment , cell associate HIV drug efficacy , cell associate HIV resistance identification cellular source HIV determine HIV cell reservoir assay plasma viral load . - Functional immune response difference base cell associate HIV-1 transcriptional activity undetectable plasma viral load . Immune responses patient HAART chronic , low level HIV replication circulate T lymphocytes undetectable plasma viral load include significant in-vitro proliferation HIV-1 p24 antigen , significant response recall antigen tetanus toxoid high response pathogen antigen compare patient HAART undetectable HIV replication memory T lymphocytes undetectable plasma viral load . - Adherence plasma derive HIV-1 virion erythrocytes . Erythrocytes sequester plasma associate HIV-1 virion whole blood patient HAART . While patient undetectable plasma viral load , correspond whole blood viral load value range 234 82,878 copy HIV-1 RNA/mL whole blood . These patient detectable whole blood viral load undetectable plasma viral load display clinically advance HIV infection . - CD4 count inexplicable response HAART . A decrease CD4 count undetectable plasma viral load may explain sequester HIV plasma virus erythrocytes low level cell associate HIV replication . - Defective/non-infectious virion : HIV-1 plasma viral load assay use differentiate infectious non-infectious defective virus particle &lt; 0.2 % circulate HIV-1 virion ( 1:477 1 : 117,803 ) infectious . Consequently , genotypic phenotypic drug resistance assay , HIV-1 tropism assay utilize HIV-1 RNA derive plasma virus HIV-1 RNA generate result mostly non-infectious defective virus . Difference nucleic acid sequence infectious non-infectious defective virus appropriately investigated relation diagnostic monitoring test . The implication utilize viral sequence predominantly non-infectious defective viral particle oppose infectious virus particle drug resistance tropism test clinical care HIV infect patient unknown . Consequently , increase evidence demonstrate CD4 count plasma viral load use fully interpret response HIV HAART . Moreover , mount data prof continue HIV-1 replication absence detectable plasma viral load generates HIV viral antigen result immune activation thereby enable HIV pathogenesis demonstrate increased level T cell turnover proliferation , apoptosis uninfected T cell well polyclonal B cell , natural killer ( NK ) cell monocyte activation . Various cell base marker associate HIV pathogenesis include immune activation marker Human Leukocyte Antigen ( HLA ) -Cell Surface Receptor ( DR ) ( HLA-DR ) , cluster differentiation 38 ( CD38 ) , cluster differentiation 69 ( CD69 ) , cluster differentiation 71 ( CD71 ) , senescence marker cluster differentiation 57 ( CD57 ) , proliferation marker Ki67 apoptosis marker cluster differentiation 95 ( CD95 ) ( FasR ) . Altogether marker HIV pathogenesis enable inflammatory response , reseed reservoir , HIV-1 evolution drug resistance , non-opportunistic disease gradual deterioration immune system . Immune function test evaluate functionality component immune system . They generally in-vitro base assay design measure outcome follow exposure lymphocytes specific antigen mitogen . The outcome may measurement immune stimulation marker secretion gamma interferon , incorporation tritiated thymidine cellular genomic DNA result lymphoproliferative cell response recall antigen and/or mitogen , case in-vivo base Tuberculin Skin Test , size skin induration site tuberculin purify protein derivative administration . Cellestis Limited - A Qiagen Company , recently develop QuantiFERON® Monitor ( QFM CST007 ) test base patent QuantiFERON® Technology provide measure cell-mediated immune function . It vitro diagnostic test use combination stimulant specifically stimulate different immune cell whole blood measure interferon-gamma release plasma ELISA ( Enzyme-linked immunosorbent assay ) . Therefore , aim study address utility QFM HIV immunocompromised set cell associate marker HIV pathogenesis influence immune function HIV Viral Reservoir assay blood test include well understand level immune function within cohort . How long take ? One visit 1 hour Dr. Gatpolintan Clinical Study Coordinator answer question , 10 minute blood draw ( nine block Dr. Gatpolintan ' office ) . Study outcome measure ( Correlation QFM CD4 count CD4/CD8 ratio ) assess , include data presentation , within average period 1 year study subject enrollment .</detailed_description>
	<mesh_term>HIV Seropositivity</mesh_term>
	<criteria>Antiretroviral drug naïve , ( never treatment , &gt; 60 day treatment ) , n=30 All plasma viral load result within last 24 month ; recent plasma viral load result value use enrollment . All CD4 result within last 24 month ; recent CD4 result use enrollment : CD4 &gt; 500/microliter ( uL ) ( n=15 ) CD4 &lt; 500/uL ( n=15 ) . Successful HAART &gt; 24 month two undetectable plasma viral load within last 12 month , n=30 All plasma viral load result within last 24 month ; two recent plasma viral load result within last 12 month must undetectable use enrollment . All CD4 result within last 24 month ; recent CD4 result use enrollment : CD4 &gt; 500/uL ( n=15 ) CD4 &lt; 500/uL ( n=15 ) . On HAART &gt; 24 month late plasma viral load &gt; 200 , n=30 All plasma viral load result within last 24 month ; recent plasma viral load result &gt; 200 used enrollment . All CD4 result within last 24 month ; recent CD4 result use enrollment : CD4 &gt; 500/uL ( n=15 ) CD4 &lt; 500/uL ( n=15 ) . HIV Uninfected Controls ( n=30 ) : Documentation HIV seronegative status time enrollment Key Exclusion Criteria HIV Infected : Primary infection : &lt; 6 month document HIV1 antibody positive test Key Exclusion Criteria drug naïve HIV Infected Ended HIV medication less 2 month study Key Exclusion Criteria HIV uninfected : On HIV1 preor post exposure prophylaxis &lt; 21 day enrolment Key Exclusion Criteria subject : &lt; 18 &gt; 65 year age Pregnant lactating subject Documented hepatitis B virus ( HBV ) and/or hepatitis C virus ( HCV ) Infection Proven suspect acute hepatitis Transient clinical manifestation ( i.e. , cold , flu , measles , etc ) . Eligible resolve Evidence gastrointestinal malabsorption syndrome , chronic inflammatory disease ( i.e . Crohn 's Disease ) chronic nausea vomit Prior history significant renal bone disease Malignancy cutaneous Kaposi 's sarcoma basal cell carcinoma &lt; 30 day vaccination . Eligible 30 day post vaccination . Current alcohol substance abuse Active , serious infection ( HIV infection ) require parenteral antimicrobial therapy within 30 day prior enrollment . Any clinical condition opinion PI , would make subject unsuitable study i.e . active cytomegalovirus ( CMV ) EpsteinBarr virus ( EBV ) infection , diabetes , Rheumatoid Arthritis , etc . Previous therapy agent systemic myelosuppressive , pancreotoxic , hepatotoxic cytotoxic potential within 3 month study start expect need therapy time enrollment On therapy suppresses bone marrow , toxic liver pancreas On ongoing therapy toxic kidney include aminoglycoside antibiotic , amphotericin B , cidofovir , cisplatin , foscarnet , IV pentamidine , agent significant nephrotoxic potential Creatinine clearance &lt; 60 mL/min On anticancer therapy On ongoing therapy immunosuppressive agent On ongoing chemotherapeutic agent On ongoing systemic corticosteroid On ongoing systemic interleukin 2 cytokine therapy Anticonvulsants ( eg . Carbamazepine , Phenytoin , Valproate ) Monoclonal antibody therapy ( eg . Muromonab OKT3 ) Any prior therapy , opinion PI , would make subject unsuitable study . How long take ? One visit 1 hour Dr. Gatpolintan Clinical Study Coordinator answer question , 10 minute blood draw ( nine block Dr. Gatpolintan ' office ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Immune function</keyword>
	<keyword>Interferon-gamma release assay</keyword>
	<keyword>Active HIV cell Reservoirs</keyword>
</DOC>